Weekly Recap | SIHUAN PHARM -9.3%, interim profit doublesWeekly Review·2 days ago, 11:47 PM00460-3.85%
Sihuan Pharma files HKEX next-day return disclosing share repurchase at HKD 0.81PUBT·Aug 27 at 05:34 AM00460-3.85%
Sihuan Pharma FY26 H1 profit attributable to owners rises 119% to RMB 224.7 million; revenue increases 1.3% to RMB 1.16 billionPUBT·Aug 26 at 05:08 AM00460-3.85%
Sihuan Pharmaceutical files board, committee roles and disclosure-responsible management listPUBT·Aug 26 at 04:38 AM00460-3.85%
SIHUAN PHARM Interim Net Profit RMB225M Up 119% YoY; No DividendAASTOCKS News·Aug 26 at 12:15 AM00460-3.85%
Sihuan Pharmaceutical Reshapes Leadership With CFO Exit and New Non-Executive DirectorTip Ranks·Aug 25 at 11:08 PM00460-3.85%
Sihuan Pharmaceutical Holdings Group (SEHK:460) Looks Pricey On 2026 Earnings GuidanceSimplywall·Jul 28 at 06:28 AM00460-3.85%
Sihuan Pharmaceutical Updates Bermuda Registered Office AddressTip Ranks·Jul 26 at 11:38 PM00460-3.85%
Sihuan Pharmaceutical Flags 217% Profit Surge on Medical Aesthetics and Portfolio GainsTip Ranks·Jul 26 at 11:08 PM00460-3.85%
Sihuan Pharmaceutical Holdings Group (SEHK:460) Following Phase III Trial Progress Is The Stock Too PriceySimplywall·Jul 3 at 07:03 AM00460-3.85%
Sihuan’s Xuanzhu Wins NMPA NDA Acceptance for New Reflux Esophagitis Use of AnaprazoleTip Ranks·Jun 29 at 11:38 PM00460-3.85%02575-4.64%
Sihuan Pharmaceutical Shareholders Approve All AGM Resolutions and Capital MandatesTip Ranks·Jun 26 at 04:14 AM00460-3.85%
Sihuan Pharmaceutical shareholders approve RMB 0.96 cent final dividend for 2025PUBT·Jun 26 at 03:43 AM00460-3.85%
Sihuan Pharma enrolls first patient in Phase III trial of anaprazole-based H. pylori eradication therapyPUBT·Jun 21 at 11:05 PM00460-3.85%
